Eosinophilic Esophagitis - Pipeline Review, H1 2014 @ http://www.researchmoz.us/eosinophilic-esophagitis-pipeline-review-h1-2014-report.html This report provides comprehensive information on the therapeutic development for Eosinophilic Esophagitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

1. Eosinophilic Esophagitis - Pipeline Review, H1 2014
Eosinophilic Esophagitis - Pipeline Review, H1 2014
Summary
Global Markets Directs, Eosinophilic Esophagitis - Pipeline Review, H1 2014, provides an overview of the Eosinophilic Esophagitiss therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Eosinophilic Esophagitis, complete with comparative analysis at various
stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and
featured news and press releases. It also reviews key players involved in the therapeutic development for Eosinophilic Esophagitis and special features on
late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built
using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and
featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug
profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the
latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that
the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by
identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Eosinophilic Esophagitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration
details & other developmental activities
- The report reviews key players involved in the therapeutics development for Eosinophilic Esophagitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Eosinophilic Esophagitis products under development by companies and universities/research institutes based on information derived from
company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Eosinophilic Esophagitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Eosinophilic Esophagitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Eosinophilic Esophagitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand
business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
table Of Contents 2
list Of Tables 4
list Of Figures 5
introduction 6
global Markets Direct Report Coverage 6
eosinophilic Esophagitis Overview 7
therapeutics Development 8
pipeline Products For Eosinophilic Esophagitis - Overview 8
pipeline Products For Eosinophilic Esophagitis - Comparative Analysis 9
eosinophilic Esophagitis - Therapeutics Under Development By Companies 10
eosinophilic Esophagitis - Pipeline Products Glance 12
late Stage Products 12
clinical Stage Products 13
early Stage Products 14
Eosinophilic Esophagitis - Pipeline Review, H1 2014

2. unknown Stage Products 15
eosinophilic Esophagitis - Products Under Development By Companies 16
eosinophilic Esophagitis - Companies Involved In Therapeutics Development 17
novartis Ag 17
aptalis Pharma Inc. 18
teva Pharmaceutical Industries Limited 19
dbv Technologies 20
meritage Pharma, Inc. 21
oxagen Limited 22
dr. Falk Pharma Gmbh 23
receptos, Inc. 24
lipella Pharmaceuticals, Inc. 25
eosinophilic Esophagitis - Therapeutics Assessment 26
assessment By Monotherapy Products 26
assessment By Target 27
assessment By Mechanism Of Action 30
assessment By Route Of Administration 33
assessment By Molecule Type 35
drug Profiles 37
reslizumab - Drug Profile 37
product Description 37
mechanism Of Action 37
r&d Progress 37
oc-459 - Drug Profile 38
product Description 38
mechanism Of Action 38
r&d Progress 38
budesonide - Drug Profile 40
product Description 40
mechanism Of Action 40
r&d Progress 40
qax-576 - Drug Profile 41
product Description 41
mechanism Of Action 41
r&d Progress 41
rpc-4046 - Drug Profile 43
product Description 43
mechanism Of Action 43
r&d Progress 43
eur-1100 - Drug Profile 44
product Description 44
mechanism Of Action 44
r&d Progress 44
drug For Eosinophilic Esophagitis - Drug Profile 45
product Description 45
mechanism Of Action 45
r&d Progress 45
tacrolimus Liposomal - Drug Profile 46
product Description 46
mechanism Of Action 46
r&d Progress 46
budesonide - Drug Profile 47
product Description 47
mechanism Of Action 47
r&d Progress 47
eosinophilic Esophagitis - Recent Pipeline Updates 50
eosinophilic Esophagitis - Dormant Projects 54
eosinophilic Esophagitis - Product Development Milestones 55
featured News & Press Releases 55
aug 13, 2012: Meritage Initiates Clinical Trial Of Oral Budesonide Suspension For Adolescent And Adult Patients With Eosinophilic Esophagitis 55
may 10, 2011: Meritage Pharma Reports Positive Phase Iib Data For Oral Budesonide Suspension In Pediatric Patients With Eosinophilic Esophagitis 55
may 10, 2011: Meritage Reports Positive Phase Iib Data For Oral Budesonide Suspension In Pediatric Patients With Eosinophilic Esophagitis 56
nov 23, 2009: Ception Therapeutics And Cephalon Provide Initial Results Of A Phase Iib/iii Study Of Cinquil In Pediatric Eosinophilic Esophagitis 57
appendix 59
methodology 59
coverage 59
secondary Research 59
primary Research 59
Eosinophilic Esophagitis - Pipeline Review, H1 2014

3. expert Panel Validation 59
contact Us 60
disclaimer 60
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your
research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and
across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an
informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Eosinophilic Esophagitis - Pipeline Review, H1 2014